<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factors to consider in assessing risk of an episode of neutropenic fever in patients undergoing cytotoxic chemotherapy for malignancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factors to consider in assessing risk of an episode of neutropenic fever in patients undergoing cytotoxic chemotherapy for malignancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Factors to consider in assessing risk of an episode of neutropenic fever in patients undergoing cytotoxic chemotherapy for malignancy</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="20%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Factors related to</td> <td class="subtitle1">Factor</td> <td class="subtitle1" colspan="2">Effect on risk</td> </tr> <tr> <td class="divider_bottom" rowspan="5">Patient characteristics</td> <td> <ul> <li>Advanced age </li> </ul> </td> <td colspan="2"> <ul> <li>Risk increases if age ≥65 years<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Performance status </li> </ul> </td> <td colspan="2"> <ul> <li>Risk increases if ECOG performance score ≥2<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Nutritional status </li> </ul> </td> <td colspan="2"> <ul> <li>Risk increases if albumin &lt;35 g/L<sup>[2,3]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Prior neutropenic fever episode </li> </ul> </td> <td colspan="2"> <ul> <li>Risk in cycles 2 to 6 is fourfold greater if neutropenic fever episode occurs in cycle 1<sup>[4]</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <ul> <li>Comorbidities </li> </ul> </td> <td colspan="2"> <ul> <li>Neutropenic fever odds increase by 27, 67, and 125% for one, two, or three or more comorbidities, respectively<sup>[1,5]</sup> </li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="16">Underlying malignancy</td> <td rowspan="13"> <ul> <li>Cancer diagnosis </li> </ul> </td> <td><strong>Diagnosis</strong></td> <td><strong>Reported neutropenic fever rates (%)</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Acute leukemia/MDS </li> </ul> </td> <td>85.0 to 95.0<sup>[6-9]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>High-grade lymphoma </li> </ul> </td> <td>35.0 to 71.0*<sup>[10]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Soft tissue sarcoma </li> </ul> </td> <td>27.0 (95% CI 19.0-34.5)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>NHL/myeloma </li> </ul> </td> <td>26.0 (95% CI 22.0-29.0)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Germ cell carcinoma </li> </ul> </td> <td>23.0 (95% CI 16.6-29.0)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Hodgkin lymphoma </li> </ul> </td> <td>15.0 (95% CI 6.6-24.0)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Ovarian carcinoma </li> </ul> </td> <td>12.0 (95% CI 6.6-17.7)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Lung cancers </li> </ul> </td> <td>10.0 (95% CI 9.8-10.7)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Colorectal cancers </li> </ul> </td> <td>5.5 (95% CI 5.1-5.8)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Head and neck carcinoma </li> </ul> </td> <td>4.6 (95% CI 1.0-8.2)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Breast cancer </li> </ul> </td> <td>4.4 (95% CI 4.1-4.7)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Prostate cancer </li> </ul> </td> <td>1.0 (95% CI 0.9-1.1)<sup>[4,5,11,12]</sup></td> </tr> <tr> <td> <ul> <li>Cancer stage </li> </ul> </td> <td colspan="2"> <ul> <li>Risk increases for advanced stage (≥2)<sup>[4]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Remission status </li> </ul> </td> <td colspan="2"> <ul> <li>Risk increases if not in remission<sup>[8,13]</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <ul> <li>Cancer treatment response </li> </ul> </td> <td colspan="2"> <ul> <li>Risk is lowest if patient has a CR </li> <li>If patient has a PR, neutropenic fever risk is greater for acute leukemia than for solid tissue malignancies<sup>[8]</sup> </li> <li>Neutropenic fever risk is higher in patients with persistent, refractory, or progressive disease despite treatment<sup>[14,15]</sup> </li> </ul> </td> </tr> <tr> <td rowspan="6">Treatment of malignancy</td> <td> <ul> <li>Cytotoxic regimen </li> </ul> </td> <td colspan="2">Risk is higher with regimens that include: <ul class="decimal_heading"> <li>Anthracyclines at doses ≥90 mg/m<sup>2</sup> </li> <li>Cisplatin at doses ≥100 mg/m<sup>2</sup> </li> <li>Ifosfamide at doses ≥9 g/m<sup>2</sup> </li> <li>Cyclophosphamide at doses ≥1 g/m<sup>2</sup> </li> <li>Etoposide at doses ≥500 mg/m<sup>2</sup> </li> <li>Cytarabine at doses ≥1 g/m<sup>2</sup> </li> <li>High dose density </li> <li>Anthracycline + taxane, and cyclophosphamide or gemcitabine, for breast cancer </li> </ul> </td> </tr> <tr> <td> <ul> <li>Dose intensity </li> </ul> </td> <td colspan="2"> <ul> <li>Increased risk if &gt;85% of scheduled doses are administered<sup>[12,16]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Degree and duration of GI and/or oral mucositis </li> </ul> </td> <td colspan="2"> <ul> <li>Risk is greatest if NCI mucositis grade is ≥3 (GI) or if peak score on OMAS is ≥2<sup>[9,17,18]</sup> </li> </ul> </td> </tr> <tr> <td rowspan="3"> <ul> <li>Degree and duration of cytopenia </li> </ul> </td> <td> <ul> <li>Profound, protracted neutropenia </li> </ul> </td> <td>ANC &lt;100/mcL for ≥7 days<sup>[19-21]</sup></td> </tr> <tr> <td> <ul> <li>Lymphopenia </li> </ul> </td> <td>ALC &lt;700/mcL (ANC surrogate)<sup>[11,22]</sup></td> </tr> <tr> <td> <ul> <li>Monocytopenia </li> </ul> </td> <td>AMC &lt;150/mcL (ANC surrogate)<sup>[23]</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">ECOG: Eastern Cooperative Oncology Group; MDS: myelodysplastic syndrome; NHL: non-Hodgkin lymphoma; CR: complete response; PR: partial response; GI: gastrointestinal; NCI: National Cancer Institute; OMAS: oral mucositis assessment scale; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; AMC: absolute monocyte count.<br/>* Grade 3 and 4 neutropenia. Treatment included colony-stimulating factors and antimicrobial prophylaxis. Rate of neutropenia varied by chemotherapy regimen.</div><div class="graphic_reference">References:

<ol>
<li>Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 2014; 90:190.</li>
<li>Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 2004; 22:4302.</li>
<li>Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. A predictive model for life threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37:351.</li>
<li>Cullen MH, Billingham LJ, Gaunt CH, et al. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007; 25:4821.</li>
<li>Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011; 19:333.</li>
<li>Bow EJ. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background, and approaches to management. In: Management of Infection in Oncology Patients, Wingard JR, Bowden RA (Eds), Martin Dunitz, London 2003. p 71.</li>
<li>Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26:5684.</li>
<li>Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.</li>
<li>Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia 2006; 20:2087.</li>
<li>Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013.</li>
<li>Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88:181.</li>
<li>Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INCEU prospective observational European neutropenia study. Support Care Cancer 2008; 16:1299.</li>
<li>Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148:2561.</li>
<li>Bow EJ, Kilpatrick MG, Scott BA, et al. Acute myeloid leukemia inManitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer 1994; 74:52.</li>
<li>Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316.</li>
<li>Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006; 14:901.</li>
<li>Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19:2201.</li>
<li>Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.</li>
<li>Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14:636.</li>
<li>Bodey GP, Rodriguez V, Chang HY, et al. Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer 1978; 41:1610.</li>
<li>Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730.</li>
<li>Oguz A, Karadeniz C, Ckitak EC, et al. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: Early lymphopenia or monocytopenia? Pediatr Hematol Oncol 2006; 23:143.</li>
<li>Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42:2433.</li>
</ol>

From: Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 2018; 36:3043. Reprinted with permission. Copyright © 2018 American Society of Clinical Oncology. All rights reserved.</div><div id="graphicVersion">Graphic 119454 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
